<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="pfcp" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">pfcp</book-part-id>
      <title-group>
        <title>Primary Familial and Congenital Polycythemia</title>
        <alt-title alt-title-type="alt-title">Synonyms: Familial Erythrocytosis Type 1, ECYT1</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bento</surname>
            <given-names>Celeste</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Department of Clinical Hematology<break/>Centro Hospitalar e Universit&#x000e1;rio de Coimbra<break/>Coimbra, Portugal</aff>
          <email>celeste.bento@chuc.min-saude.pt</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>McMullin</surname>
            <given-names>Mary Frances</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Department of Haematology<break/>Queens University<break/>Belfast, Northern Ireland</aff>
          <email>m.mcmullin@qub.ac.uk</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Percy</surname>
            <given-names>Melanie</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Department of Haematology<break/>Belfast City Hospital<break/>Belfast, Northern Ireland</aff>
          <email>m.percy@qub.ac.uk</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cario</surname>
            <given-names>Holger</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Department of Paediatrics and Adolescent Medicine<break/>University Medical Center Ulm<break/>Ulm, Germany</aff>
          <email>holger.cario@uniklinik-ulm.de</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>10</day>
          <month>11</month>
          <year>2016</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="glc" document-type="chapter">Primary Congenital Glaucoma</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="bgc" document-type="chapter">Primary Familial Brain Calcification</related-object>
      <abstract id="pfcp.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Primary familial and congenital polycythemia (PFCP) is characterized by isolated erythrocytosis in an individual with a normal-sized spleen and absence of disorders causing secondary erythrocytosis. Clinical manifestations relate to the erythrocytosis and can include plethora, the hyperviscosity syndrome (headache, dizziness, fatigue, lassitude, visual and auditory disturbances, paraesthesia, myalgia), altered mental status caused by hypoperfusion and local hypoxia, and arterial and/or venous thromboembolic events. Although the majority of individuals with PFCP have only mild manifestations of hyperviscosity such as dizziness or headache, some affected individuals have had severe and even fatal complications including arterial hypertension, intracerebral hemorrhage, deep vein thrombosis, coronary disease, and myocardial infarction. To date 116 affected individuals from 24 families have been reported.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of PFCP is established in a proband with isolated erythrocytosis (hemoglobin and hematocrit above the normal reference range when adjusted for age and sex), normal hemoglobin oxygen affinity measured as P<sub>50</sub>, erythropoietin (EPO) serum level below or in the lower normal range for laboratory-specific reference values, and a family history consistent with autosomal dominant inheritance. The diagnosis of PFCP can be confirmed in 12%-15% of individuals with these findings by detection of a heterozygous pathogenic variant in <italic toggle="yes">EPOR</italic> by molecular genetic testing.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> No management guidelines have been published. While the majority of individuals with PFCP require no regular treatment, some undergo phlebotomy to either treat symptoms of the hyperviscosity syndrome or to maintain the hematocrit at an almost normal level. Some patients require antihypertensive therapy. While low-dose aspirin can be considered for the prevention of thromboembolic events, no evidence of efficacy exists.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> Maintain good hydration and avoid activities that potentially increase blood viscosity (e.g., mountain climbing, scuba diving, smoking). For those at increased risk for thromboembolic events: take precautions in higher-risk situations such as long-distance airline flights</p>
          <p><italic toggle="yes">Surveillance:</italic> Regular cardiology assessment including cardiac function (echocardiography) and blood pressure measurement. Life-long assessment for manifestations/severity of hyperviscosity syndrome and investigation of any suspicious clinical events such as thromboembolic complications.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Dehydration; activities that could increase blood viscosity (mountain climbing, scuba diving, smoking)</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Presymptomatic diagnosis is warranted in relatives at risk in order to identify as early as possible those who would benefit from education about agents and circumstances to avoid including inappropriate treatments.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>PFCP is inherited in an autosomal dominant manner. Each child of an individual with PFCP has a 50% chance of inheriting the <italic toggle="yes">EPOR</italic> pathogenic variant. Once the <italic toggle="yes">EPOR</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for PFCP are possible options; note, however, that molecular genetic test results cannot predict disease onset or severity.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="pfcp.Diagnosis">
        <title>Diagnosis</title>
        <p>The consensus recommendations for the diagnosis of absolute erythrocytosis in children established by the Network of Experts on the Molecular Diagnosis of Myeloproliferative Neoplasm (MPN) and MPN-related congenital diseases (MPNr) (MPN &#x00026; MPNr-Euronet) are mainly based on measurement of serum erythropoietin (EPO) level and hemoglobin oxygen affinity measured as P<sub>50</sub>. Definitive diagnosis requires identification of a pathogenic variant (or variants) in one of the known genes [<xref ref-type="bibr" rid="pfcp.REF.cario.2013.1734">Cario et al 2013</xref>].</p>
        <sec id="pfcp.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Primary familial and congenital polycythemia (PFCP) <bold>should be suspected</bold> in individuals with the following clinical findings, laboratory findings, and family history.</p>
          <p>
            <bold>Clinical findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>No splenomegaly</p>
            </list-item>
            <list-item>
              <p>Absence of cardiac, pulmonary, and renal disease causing secondary erythrocytosis</p>
            </list-item>
          </list>
          <p>
            <bold>Laboratory findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Complete blood count that shows isolated absolute erythrocytosis:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Normal platelet and white cell counts, which demonstrate non-involvement of other hematopoietic cell lines and confirm isolated erythrocytosis</p>
                </list-item>
                <list-item>
                  <p>Hemoglobin and hematocrit in at least two separate blood counts performed at different times that are above the normal reference range (adjusted to age and sex) and confirm absolute erythrocytosis</p>
                  <p>Note: Absolute erythrocytosis is distinct from: (1) relative erythrocytosis, caused by severe reduction in plasma volume (e.g., due to diuretics or severe diarrhea) and (2) apparent erythrocytosis, caused by arterial hypoxemia (e.g., cigarette smoking, carbon monoxide poisoning, or sleep apnea) (reviewed in <xref ref-type="bibr" rid="pfcp.REF.mcmullin.2005.174">McMullin et al [2005]</xref>).</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Normal hemoglobin oxygen affinity measured as P<sub>50</sub> (i.e., the partial pressure of oxygen in the blood at which hemoglobin is 50% saturated)</p>
            </list-item>
            <list-item>
              <p>Erythropoietin (EPO) serum level that is below or in the lower normal range (based on laboratory-specific reference values), which excludes secondary erythrocytosis associated with an increased serum EPO level (see <xref ref-type="sec" rid="pfcp.Differential_Diagnosis">Differential Diagnosis</xref>)</p>
            </list-item>
          </list>
          <p><bold>Family history.</bold> Other affected relatives in a pattern consistent with autosomal dominant inheritance</p>
        </sec>
        <sec id="pfcp.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of PFCP <bold>can be established</bold> in a proband when:</p>
          <list list-type="bullet">
            <list-item>
              <p>Clinical findings alone support the diagnosis (i.e., isolated absolute erythrocytosis, normal P<sub>50</sub>, EPO serum level below or in the lower normal range, and a positive family history consistent with autosomal dominant inheritance);</p>
              <p>AND/OR</p>
            </list-item>
            <list-item>
              <p>A heterozygous pathogenic variant in <italic toggle="yes">EPOR</italic> is identified by molecular genetic testing in a proband who represents a simplex case (i.e., a single occurrence in a family) and has some (not all) suggestive findings.</p>
            </list-item>
          </list>
          <p>Molecular genetic testing approaches can include <bold>single-gene testing</bold> when clinical findings strongly support the diagnosis of PFCP or use of a <bold>multi-gene panel</bold> in those with suggestive, but not diagnostic, clinical findings:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis identifies a pathogenic <italic toggle="yes">EPOR</italic> variant in 12%-15% of individuals with isolated erythrocytosis and low serum EPO levels [<xref ref-type="bibr" rid="pfcp.REF.kralovics.2001.115">Kralovics &#x00026; Prchal 2001</xref>, <xref ref-type="bibr" rid="pfcp.REF.rives.2007.674">Rives et al 2007</xref>, <xref ref-type="bibr" rid="pfcp.REF.alsheikh.2008.1072">Al-Sheikh et al 2008</xref>]. Use of deletion/duplication analysis as a next step can be considered; however, to date no <italic toggle="yes">EPOR</italic> deletions or duplications causative of PFCP have been reported.</p>
            </list-item>
            <list-item>
              <p><bold>Use of a multi-gene panel</bold> that includes <italic toggle="yes">EPOR</italic> and the genes causing secondary erythrocytosis (<italic toggle="yes">HBB</italic>, <italic toggle="yes">BPGM</italic>, <italic toggle="yes">VHL</italic>, <italic toggle="yes">EGLN1</italic>, and <italic toggle="yes">EPAS1</italic>) (see <xref ref-type="sec" rid="pfcp.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered, especially for probands who either represent simplex cases (i.e., a single occurrence of PFCP in a family) and/or in whom secondary causes of erythrocytosis have not been excluded. Note: The genes included in the panel and the diagnostic sensitivity of the testing used for each gene varies by laboratory and over time.</p>
            </list-item>
          </list>
          <table-wrap id="pfcp.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Primary Familial Congenital Polycythemia</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_pfcp.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_pfcp.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_pfcp.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_pfcp.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">EPOR</italic>
                  </td>
                  <td headers="hd_h_pfcp.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_pfcp.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">12%-15%&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_pfcp.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_pfcp.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">None reported to date</td>
                </tr>
                <tr>
                  <td headers="hd_h_pfcp.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown</td>
                  <td headers="hd_h_pfcp.T.molecular_genetic_testing_used_in_1_1_1_2 hd_h_pfcp.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" colspan="2" align="left" rowspan="1">85%-88%&#x000a0;<sup>6</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="pfcp.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="pfcp" object-id="pfcp.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="pfcp.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="pfcp.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="pfcp.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="pfcp.TF.1.4">
                <label>4. </label>
                <p><xref ref-type="bibr" rid="pfcp.REF.kralovics.2001.115">Kralovics &#x00026; Prchal [2001]</xref>, <xref ref-type="bibr" rid="pfcp.REF.rives.2007.674">Rives et al [2007]</xref>, <xref ref-type="bibr" rid="pfcp.REF.alsheikh.2008.1072">Al-Sheikh et al [2008]</xref></p>
              </fn>
              <fn id="pfcp.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="pfcp.TF.1.6">
                <label>6. </label>
                <p>Because <italic toggle="yes">EPOR</italic> pathogenic variants are found in only 12%-15% of individuals with PFCP, mutation of at least one other yet-to-be-identified gene may also be causative, such as one involved in the EPOR signaling pathway or an erythropoiesis-regulating pathway [<xref ref-type="bibr" rid="pfcp.REF.kralovics.2001.115">Kralovics &#x00026; Prchal 2001</xref>, <xref ref-type="bibr" rid="pfcp.REF.jedlickova.2003.327">Jedlickova et al 2003</xref>, <xref ref-type="bibr" rid="pfcp.REF.bourantas.2006.537">Bourantas et al 2006</xref>]. One possible candidate gene is <italic toggle="yes">SH2B3 (</italic>encoding SH2B adapter protein 3) as germline <italic toggle="yes">SH2B3</italic> pathogenic variants have been detected in several individuals with idiopathic erythrocytosis [<xref ref-type="bibr" rid="pfcp.REF.mcmullin.2016.248">McMullin &#x00026; Cario 2016</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Test characteristics.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/v20/n5/full/ejhg2011252a.html">Clinical Utility Gene Card</ext-link> [<xref ref-type="bibr" rid="pfcp.REF.hussein.2012">Hussein et al 2012</xref>] for information on test characteristics including sensitivity and specificity.</p>
        </sec>
      </sec>
      <sec id="pfcp.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="pfcp.Clinical_Description">
          <title>Clinical Description</title>
          <p>Primary familial congenital polycythemia (PFCP) is characterized by isolated erythrocytosis. To date, PFCP caused by inherited pathogenic variants in <italic toggle="yes">EPOR</italic> has been reported in 116 individuals from 24 families [<xref ref-type="bibr" rid="pfcp.REF.bento.2014.15">Bento et al 2014</xref>]. The little information available on its clinical presentation is derived from case reports and the experience of the authors.</p>
          <p>Clinical manifestations of PFCP comprise plethora, arterial and venous thromboembolic events, and symptoms caused by increased blood viscosity leading to hypoperfusion and local hypoxia. The hyperviscosity syndrome is characterized by symptoms including headache, dizziness, fatigue, lassitude, visual and auditory disturbances, paraesthesia, and myalgia, and may be associated with altered mental status. Of note, the majority of individuals with PFCP have only mild manifestations with hyperviscosity symptoms such as dizziness or headache.</p>
          <p>PFCP has been detected &#x02013; either by chance or due to symptoms &#x02013; in several children ages six months to 16 years [<xref ref-type="bibr" rid="pfcp.REF.arcasoy.1997.4628">Arcasoy et al 1997</xref>, <xref ref-type="bibr" rid="pfcp.REF.furukawa.1997.222">Furukawa et al 1997</xref>, <xref ref-type="bibr" rid="pfcp.REF.percy.1998.407">Percy et al 1998</xref>, <xref ref-type="bibr" rid="pfcp.REF.petersen.2004.537">Petersen et al 2004</xref>, <xref ref-type="bibr" rid="pfcp.REF.rives.2007.674">Rives et al 2007</xref>]. Patient hematocrits ranged from 57% to 63%. Clinical manifestations (present in some, but not all) were usually relatively mild (predominantly chronic headache and plethora) and relieved by phlebotomy (see <xref ref-type="sec" rid="pfcp.Management">Management</xref>).</p>
          <p>In contrast, some affected individuals have had severe and even fatal clinical complications such as arterial hypertension, intracerebral hemorrhage, deep vein thrombosis, coronary disease, and myocardial infarction [<xref ref-type="bibr" rid="pfcp.REF.prchal.1995.1831">Prchal et al 1995</xref>, <xref ref-type="bibr" rid="pfcp.REF.sokol.1995.15">Sokol et al 1995</xref>, <xref ref-type="bibr" rid="pfcp.REF.kralovics.1997.2057">Kralovics et al 1997</xref>, <xref ref-type="bibr" rid="pfcp.REF.kralovics.1998.124">Kralovics et al 1998</xref>].</p>
          <p>The age at diagnosis and the clinical findings vary even within the same family. The descriptions of reported families/cases are examples of the clinical variability observed in this disorder even within the same family.</p>
          <p>One of the first families described with PFCP included four affected individuals in three generations who were subsequently found to be heterozygous for a nonsense <italic toggle="yes">EPOR</italic> pathogenic variant [<xref ref-type="bibr" rid="pfcp.REF.prchal.1985.1208">Prchal et al 1985</xref>, <xref ref-type="bibr" rid="pfcp.REF.kralovics.1998.124">Kralovics et al 1998</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>The proband, who had extensive coronary artery disease and arterial hypertension, died at age 58 years from hemorrhagic stroke.</p>
            </list-item>
            <list-item>
              <p>Another family member had hypertension and a myocardial infarction at age 40 years.</p>
            </list-item>
            <list-item>
              <p>The father of a young girl (who initially appeared to be unaffected) had arterial hypertension beginning at age 20 years and one episode of deep vein thrombosis; as a young girl his daughter had a normal blood count but EPO hypersensitivity in erythroid precursor cells (similar to that observed in the 3 other affected family members).</p>
            </list-item>
          </list>
          <p>In another family, all three affected individuals were found to have a heterozygous <italic toggle="yes">EPOR</italic> nonsense pathogenic variant [<xref ref-type="bibr" rid="pfcp.REF.rives.2007.674">Rives et al 2007</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>The proband, a 14-year old boy, was diagnosed with erythrocytosis during evaluation by a pediatric endocrinologist for apparent gynecomastia.</p>
            </list-item>
            <list-item>
              <p>The mother had had confirmed erythrocytosis during childhood and adolescence; at age 27 years her hemoglobin had been 175 g/L. At the time of the diagnosis of the proband, her hemoglobin was normal; however, her low serum ferritin concentration and transferrin saturation suggested that iron deficiency could be the explanation for her normal hematologic findings.</p>
            </list-item>
            <list-item>
              <p>The brother of the proband had experienced a deep vein thrombosis at age 18 years. Additional hyperviscosity symptoms which occurred intermittently were relieved by phlebotomies.</p>
            </list-item>
          </list>
          <p>A large Finnish family with congenital erythrocytosis (including an Olympic medalist in cross-country skiing) was found to have a heterozygous nonsense <italic toggle="yes">EPOR</italic> pathogenic variant [<xref ref-type="bibr" rid="pfcp.REF.de_la_chapelle.1993.4495">de la Chapelle et al 1993</xref>].</p>
          <p>In a family heterozygous for an <italic toggle="yes">EPOR</italic> pathogenic variant [<xref ref-type="bibr" rid="pfcp.REF.sokol.1995.15">Sokol et al 1995</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>The proband experienced an occipital hemorrhage at age 29 years.</p>
            </list-item>
            <list-item>
              <p>His two daughters developed asymptomatic erythrocytosis.</p>
            </list-item>
            <list-item>
              <p>His mother reported headaches and feeling &#x0201c;sluggish,&#x0201d; but had not experienced cerebral or coronary vascular accidents.</p>
            </list-item>
          </list>
          <p>A pathogenic <italic toggle="yes">EPOR</italic> nonsense variant, predicted to result in the shortest truncated EPOR reported to date, was identified in a woman age 30 years followed since childhood for asymptomatic erythrocytosis of unknown cause. Her hemoglobin was 206 g/L, her hematocrit was 61%, and serum EPO level was low; she did not have splenomegaly [<xref ref-type="bibr" rid="pfcp.REF.chauveau.2016.475">Chauveau et al 2016</xref>].</p>
          <p><italic toggle="yes">EPOR</italic> missense variants of uncertain significance were found in a man age 35 years who required regular phlebotomy and in a person age 52 years with a clinical history of recurrent venous thrombosis but no family history of hematologic disorders [<xref ref-type="bibr" rid="pfcp.REF.bento.2013.361">Bento et al 2013</xref>, <xref ref-type="bibr" rid="pfcp.REF.chauveau.2016.475">Chauveau et al 2016</xref>].</p>
          <p><bold>Other laboratory findings.</bold> Bone marrow erythroid progenitor colonies exhibit EPO hypersensitivity.</p>
        </sec>
        <sec id="pfcp.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Given the small number of reported affected individuals to date, it has not been possible to identify any genotype-phenotype correlations; however, it is notable that the age at diagnosis and the clinical findings vary even within the same family.</p>
        </sec>
        <sec id="pfcp.Penetrance">
          <title>Penetrance</title>
          <p>Data are insufficient to draw any conclusions about penetrance.</p>
        </sec>
        <sec id="pfcp.Prevalence">
          <title>Prevalence</title>
          <p>Primary familial and congenital polycythemia (PFCP) is a rare disorder; the prevalence is not known. To date, PFCP caused by inherited heterozygous pathogenic variant in <italic toggle="yes">EPOR</italic> has been reported in 116 individuals in 24 families [<xref ref-type="bibr" rid="pfcp.REF.bento.2014.15">Bento et al 2014</xref>].</p>
        </sec>
      </sec>
      <sec id="pfcp.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">EPOR</italic>.</p>
      </sec>
      <sec id="pfcp.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Causes of erythrocytosis to be considered in the differential diagnosis of primary familial and congenital polycythemia (PFCP) include:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Acquired primary erythrocytosis</bold> (polycythemia vera due to a somatic <italic toggle="yes">JAK2</italic> pathogenic variant)</p>
          </list-item>
          <list-item>
            <p><bold>Secondary erythrocytosis,</bold> which can result from:</p>
            <list list-type="bullet">
              <list-item>
                <p>Events extrinsic to the erythroid compartment (e.g., cardiac or pulmonary insufficiency) which induce hypoxia and increase the production of EPO resulting in erythrocytosis;</p>
              </list-item>
              <list-item>
                <p>Inherited variants that result in high oxygen affinity of hemoglobin causing tissue hypoxia, such as:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Variants in <italic toggle="yes">HBB</italic> (encoding <related-object link-type="booklink" source-id="gene" document-id="b-thal" document-type="chapter">hemoglobin subunit beta</related-object>) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/141900">OMIM</ext-link>) or <italic toggle="yes">HBA1</italic> (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/141800">OMIM</ext-link>) and HBA2 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/141850">OMIM</ext-link>) (encoding <related-object link-type="booklink" source-id="gene" document-id="a-thal" document-type="chapter">hemoglobin subunit alpha</related-object>);</p>
                    <p>OR</p>
                  </list-item>
                  <list-item>
                    <p>Variants in <italic toggle="yes">BPGM</italic> that result in erythrocyte bisphosphoglycerate mutase (2,3- BPG) deficiency (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/222800">OMIM</ext-link>)<italic toggle="yes">.</italic></p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>Inherited variants in some of the genes encoding oxygen-sensing pathway proteins, such as: <italic toggle="yes">EGLN1</italic>, <italic toggle="yes">EPAS1</italic>, and <related-object link-type="booklink" source-id="gene" document-id="vhl" document-type="chapter"><italic toggle="yes">VHL</italic></related-object> (reviewed in <xref ref-type="bibr" rid="pfcp.REF.bento.2014.15">Bento et al [2014]</xref>; for diagnostic algorithms see <xref ref-type="bibr" rid="pfcp.REF.bento.2013.361">Bento et al [2013]</xref> and <xref ref-type="bibr" rid="pfcp.REF.cario.2013.1734">Cario et al [2013]</xref>).</p>
              </list-item>
            </list>
          </list-item>
        </list>
      </sec>
      <sec id="pfcp.Management">
        <title>Management</title>
        <sec id="pfcp.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with primary familial congenital polycythemia (PFCP), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Full blood counts with evaluation of white blood cells and of platelets, if not performed at the time of diagnosis</p>
            </list-item>
            <list-item>
              <p>Cardiology assessment including cardiac function (echocardiography) and blood pressure measurement. In case of increased blood pressure, perform 24-hour measurement.</p>
            </list-item>
            <list-item>
              <p>Recording of symptoms of hyperviscosity syndrome and their severity:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Hyperviscosity syndrome symptoms:</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>Headache</p>
                    </list-item>
                    <list-item>
                      <p>Dizziness</p>
                    </list-item>
                    <list-item>
                      <p>Altered mentation, sense of distance</p>
                    </list-item>
                    <list-item>
                      <p>Visual disturbances</p>
                    </list-item>
                    <list-item>
                      <p>Tinnitus</p>
                    </list-item>
                    <list-item>
                      <p>Paraesthesia</p>
                    </list-item>
                    <list-item>
                      <p>Low performance</p>
                    </list-item>
                    <list-item>
                      <p>Fatigue, lassitude</p>
                    </list-item>
                    <list-item>
                      <p>Myalgia, muscle weakness</p>
                    </list-item>
                  </list>
                </list-item>
                <list-item>
                  <p>Hyperviscosity syndrome severity:</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>Grade 1. Mild; does not interfere with normal activities</p>
                    </list-item>
                    <list-item>
                      <p>Grade 2. Moderate; interferes with some activities</p>
                    </list-item>
                    <list-item>
                      <p>Grade 3. Marked to severe; interferes with most or all activities</p>
                    </list-item>
                  </list>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="pfcp.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>No management guidelines have been published.</p>
          <p>The majority of individuals with PFCP require no regular treatment.</p>
          <p>In some individuals with PFCP, antihypertensive treatment and phlebotomies are initiated either:</p>
          <list list-type="bullet">
            <list-item>
              <p>When symptoms of the hyperviscosity syndrome are evident;</p>
              <p>OR</p>
            </list-item>
            <list-item>
              <p>At routine intervals to maintain the hematocrit at an almost normal level.</p>
            </list-item>
          </list>
          <p>While low-dose aspirin can be considered for the prevention of thromboembolic events, no evidence of efficacy exists. Of note, at least one individual (a male age 40 yrs) died from myocardial infarction despite regularly performed phlebotomies [<xref ref-type="bibr" rid="pfcp.REF.prchal.1996.263">Prchal &#x00026; Sokol 1996</xref>].</p>
          <p><bold>Hyperviscosity symptoms (see</bold>
<xref ref-type="sec" rid="pfcp.Evaluations_Following_Initial_Diagn"><bold>Evaluations Following Initial Diagnosis</bold></xref><bold>)</bold></p>
          <list list-type="bullet">
            <list-item>
              <p>Grade 1. Consider aspirin treatment.</p>
            </list-item>
            <list-item>
              <p>Grade 2. Consider aspirin treatment. In the presence of persistent symptoms perform phlebotomy. In the event of recurrent episodes consider regular phlebotomy to maintain the hematocrit in the age-respective normal range.</p>
            </list-item>
            <list-item>
              <p>Grade 3. Consider regular phlebotomy to maintain hematocrit in the age-respective normal range. Consider additional aspirin treatment.</p>
            </list-item>
          </list>
          <p>
            <bold>Thromboembolic events</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Provide acute treatment according to established practice for the event.</p>
            </list-item>
            <list-item>
              <p>Evaluate for other thrombophilic risk factors.</p>
            </list-item>
            <list-item>
              <p>Start regular phlebotomy to maintain hematocrit in the age-respective normal range. Consider additional aspirin treatment in all patients.</p>
            </list-item>
            <list-item>
              <p>Consider life-long anticoagulation (e.g., heparins, warfarin) when other severe additional risk factors are present or thromboembolic events have recurred.</p>
            </list-item>
          </list>
        </sec>
        <sec id="pfcp.Prevention_of_Primary_Manifestation">
          <title>Prevention of Primary Manifestations</title>
          <p>Always maintain good hydration.</p>
          <p>Avoid activities that potentially increase blood viscosity (e.g., mountain climbing, scuba diving, smoking).</p>
          <p>For those at increased risk for thromboembolic events: take precautions in higher-risk situations such as long-distance airline flights.</p>
        </sec>
        <sec id="pfcp.Surveillance">
          <title>Surveillance</title>
          <p>The following are appropriate:</p>
          <list list-type="bullet">
            <list-item>
              <p>Regular cardiology assessment including cardiac function (echocardiography) and blood pressure measurement. In case of occasionally increased blood pressure, perform 24-hour measurement.</p>
            </list-item>
            <list-item>
              <p>Regular life-long follow up with investigation of any suspicious clinical events such as thromboembolic complications and symptoms that could be related to hyperviscosity</p>
            </list-item>
            <list-item>
              <p>Regular life-long follow up to record manifestations of hyperviscosity syndrome and their severity (see <xref ref-type="sec" rid="pfcp.Evaluations_Following_Initial_Diagn">Evaluations Following Initial Diagnosis</xref>)</p>
            </list-item>
          </list>
        </sec>
        <sec id="pfcp.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Avoid:</p>
          <list list-type="bullet">
            <list-item>
              <p>Dehydration;</p>
            </list-item>
            <list-item>
              <p>Any activity that would potentially increase blood viscosity.</p>
            </list-item>
          </list>
        </sec>
        <sec id="pfcp.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate apparently asymptomatic older and younger at-risk relatives of an affected individual in order to identify as early as possible those with PFCP who would benefit from education regarding <xref ref-type="sec" rid="pfcp.AgentsCircumstances_to_Avoid">agents and circumstances to avoid</xref> and inappropriate treatments. Evaluations can include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>If the <italic toggle="yes">EPOR</italic> pathogenic variant in the family is known.</bold> Molecular genetic testing</p>
            </list-item>
            <list-item>
              <p><bold>If no pathogenic variant has been identified in the family.</bold> Blood count and serum EPO concentration if hemoglobin and hematocrit are increased</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="pfcp.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="pfcp.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>No information is available on the management of pregnancy in a woman with PFCP.</p>
          <p>Although the only survey of pregnancy in women with congenital erythrocytosis did not include any women with an <italic toggle="yes">EPOR</italic> pathogenic variant, data showed that when treated with low-dose aspirin and phlebotomy to reduce the hematocrit to a suitable level, women with erythrocytosis can have normal pregnancies and give birth to healthy children [<xref ref-type="bibr" rid="pfcp.REF.mcmullin.2015.586">McMullin et al 2015</xref>].</p>
        </sec>
        <sec id="pfcp.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="pfcp.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="pfcp.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Primary familial congenital polycythemia (PFCP) is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="pfcp.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed with PFCP have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with PFCP may have the disorder as the result of a <italic toggle="yes">de novo EPOR</italic> pathogenic variant. Because simplex cases (i.e., a single occurrence in a family) have not been evaluated sufficiently to determine if the pathogenic variant occurred <italic toggle="yes">de novo</italic>, the proportion of PFCP caused by a <italic toggle="yes">de novo</italic> pathogenic variant is unknown.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">EPOR</italic> pathogenic variant found in the proband cannot be detected in leukocyte DNA of either parent, possible explanations include a <italic toggle="yes">de novo</italic> pathogenic variant in the proband or germline mosaicism in a parent (although no instances of germline mosaicism have been reported, it remains a possibility).</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include a complete blood count for determination of hemoglobin and molecular genetic testing for the <italic toggle="yes">EPOR</italic> pathogenic variant identified in the proband.</p>
            </list-item>
            <list-item>
              <p>The family history of some individuals diagnosed with PFCP may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disorder in the affected parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or molecular genetic testing have been performed on the parents of the proband.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband.</bold> The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents:</p>
          <list list-type="bullet">
            <list-item>
              <p>If a parent of the proband is affected, the risk to the sibs of inheriting the pathogenic variant is 50%. However, because of the clinical variability observed in this disorder even within the same family, clinical findings and age at diagnosis cannot be predicted in sibs who inherit a pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">EPOR</italic> pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is presumed to be slightly greater than that of the general population (though still &#x0003c;1%) because of the theoretic possibility of parental germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with PFCP has a 50% chance of inheriting the <italic toggle="yes">EPOR</italic> pathogenic variant.</p>
          <p><bold>Other family members.</bold> The risk to other family members depends on the status of the proband's parents: if a parent is affected, his or her family members may be at risk.</p>
        </sec>
        <sec id="pfcp.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="pfcp.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant</bold>. When neither parent of a proband with PFCP has the <italic toggle="yes">EPOR</italic> pathogenic variant or clinical evidence of the disorder, the <italic toggle="yes">EPOR</italic> pathogenic variant is likely <italic toggle="yes">de novo</italic>. However, non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="pfcp.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">EPOR</italic> pathogenic variant has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible options. However, because of the clinical variability observed in PFCP even within the same family, molecular genetic test results cannot predict clinical findings and age at diagnosis.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="pfcp.Resources">
        <title>Resources</title>
      </sec>
      <sec id="pfcp.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="pfcp.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">EPOR</italic> comprises eight coding exons. The primary transcript (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000121.3">NM_000121.3</ext-link>) is 2459 nucleotides in length. Alternatively spliced forms of the EPO receptor have been identified, one of which has a truncated cytoplasmic domain. This shorter transcript is expressed at high levels in immature erythroid progenitor cells. In contrast, the expression of the full-length receptor increases as progenitor cells mature [<xref ref-type="bibr" rid="pfcp.REF.nakamura.1992.1138">Nakamura et al 1992</xref>]. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="pfcp" object-id="pfcp.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Variants of uncertain significance.</bold> Three <italic toggle="yes">EPOR</italic> missense variants (c.1310G&#x0003e;A, c.1462C&#x0003e;T, c.1460A&#x0003e;G) have been described for which the association with PFCP has not yet been clarified.</p>
          <list list-type="bullet">
            <list-item>
              <p>The c.1310G&#x0003e;A variant was described in a male age 35 years who required regular phlebotomy but also in a patient age 52 years with a clinical history of recurrent venous thrombosis, with normal hemoglobin and hematocrit levels and no familial history of hematologic disorders [<xref ref-type="bibr" rid="pfcp.REF.bento.2013.361">Bento et al 2013</xref>, <xref ref-type="bibr" rid="pfcp.REF.chauveau.2016.475">Chauveau et al 2016</xref>].</p>
            </list-item>
            <list-item>
              <p>The c.1462C&#x0003e;T variant was found in a white male age 42 years with sporadic primary polycythemia and in his non-polycythemic mother [<xref ref-type="bibr" rid="pfcp.REF.sokol.1994.447">Sokol et al 1994</xref>].</p>
            </list-item>
          </list>
          <p><bold>Pathogenic allelic variants.</bold> To date, about 20 pathogenic variants have been described in association with PFCP with most (if not all) located in exon 8, which encodes the C-terminal negative regulatory domain of the protein. Pathogenic variants are mostly nonsense or frameshift variants (due to small intragenic deletions or insertions) that predict or result in cytoplasmic truncation of the receptor and loss of the C-terminal negative regulatory domain. Of note, not all the mechanisms by which pathogenic variants induce erythrocytosis are fully understood at present.</p>
          <p>The founder variant, c.1316G&#x0003e;A, identified in 29 individuals from one Finnish family was predicted to truncate the EPO receptor by 70 amino acids at the C-terminal cytoplasmic domain [<xref ref-type="bibr" rid="pfcp.REF.de_la_chapelle.1993.4495">de la Chapelle et al 1993</xref>]. The same variant was also identified as a <italic toggle="yes">de novo</italic> variant in an English boy [<xref ref-type="bibr" rid="pfcp.REF.percy.1998.407">Percy et al 1998</xref>].</p>
          <p>The pathogenic variant, c.1317G&#x0003e;A, giving rise to the same amino acid substitution (p.Trp439Ter), was also identified as a <italic toggle="yes">de novo</italic> variant in a Spanish newborn [<xref ref-type="bibr" rid="pfcp.REF.rives.2007.674">Rives et al 2007</xref>].</p>
          <table-wrap id="pfcp.T.epor_variants_discussed_in_this_g" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p><italic toggle="yes">EPOR</italic> Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                  <th id="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                  <th id="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Uncertain Significance</bold>
                  </td>
                  <td headers="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1310G&#x0003e;A</td>
                  <td headers="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg437His</td>
                  <td headers="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_4" rowspan="5" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000121.3">NM_000121.3</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000112.1">NP_000112.1</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1460A&#x0003e;G</td>
                  <td headers="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Asn487Ser</td>
                </tr>
                <tr>
                  <td headers="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1462C&#x0003e;T</td>
                  <td headers="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Pro488Ser</td>
                </tr>
                <tr>
                  <td headers="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Pathogenic</bold>
                  </td>
                  <td headers="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.1316G&#x0003e;A</td>
                  <td headers="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Trp439Ter</td>
                </tr>
                <tr>
                  <td headers="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1317G&#x0003e;A</td>
                  <td headers="hd_h_pfcp.T.epor_variants_discussed_in_this_g_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Trp439Ter</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> EPOR, a glycoprotein of about 60 kd and 508 amino acids which belongs to the cytokine class I receptor family, is a transmembrane receptor consisting of: an extracellular domain that changes conformation upon EPO binding, a hydrophobic transmembrane domain, and a cytoplasmic domain with eight tyrosine residues, serving as phosphorylation sites for proteins involved in downstream signal transduction [<xref ref-type="bibr" rid="pfcp.REF.lacombe.1999.22">Lacombe &#x00026; Mayeux 1999</xref>].</p>
          <p>EPOR dimerization activates cytoplasmic tyrosine Janus kinases 2 (JAK2) activity, enabling phosphorylation of some of the tyrosine residues present in the cytoplasmic domain of EPOR [<xref ref-type="bibr" rid="pfcp.REF.lodish.1992.95">Lodish et al 1992</xref>, <xref ref-type="bibr" rid="pfcp.REF.witthuhn.1993.227">Witthuhn et al 1993</xref>, <xref ref-type="bibr" rid="pfcp.REF.miura.1994.1501">Miura et al 1994</xref>, <xref ref-type="bibr" rid="pfcp.REF.damen.1996.1455">Damen &#x00026; Krystal 1996</xref>].</p>
          <p>Following phosphorylation of EPOR, a number of other signal transduction proteins also become phosphorylated and initiation of the signal transduction pathways occurs. One such signal transducer and activator of transcription, the protein STAT5, binds to phosphorylated tyrosine present on the cytoplasmic tail of EPOR and itself becomes phosphorylated at the level of tyrosine residues [<xref ref-type="bibr" rid="pfcp.REF.damen.1995.5557">Damen et al 1995</xref>, <xref ref-type="bibr" rid="pfcp.REF.gobert.1996.2434">Gobert et al 1996</xref>].</p>
          <p>Phosphorylated STAT5 dissociates from the receptor, dimerizes, and is translocated from the cytoplasm to the nucleus, where it activates the expression of several anti-apoptotic genes in erythroid cells, most notably <italic toggle="yes">BCL2L1,</italic> through a direct binding at the level of STAT5-binding consensus sequences present in the promoter of <italic toggle="yes">BCL2L1.</italic></p>
          <p>These effects of STAT5 on <italic toggle="yes">BCL2L1</italic> activation provide the molecular basis of the anti-apoptotic effects elicited by STAT5 in erythroid cell lines [<xref ref-type="bibr" rid="pfcp.REF.nosaka.1999.4754">Nosaka et al 1999</xref>, <xref ref-type="bibr" rid="pfcp.REF.socolovsky.1999.181">Socolovsky et al 1999</xref>, <xref ref-type="bibr" rid="pfcp.REF.james.2005.546">James et al 2005</xref>].</p>
          <p>Control of intensity and duration of EPO-EPOR signaling is necessary to tightly regulate erythropoiesis. An ubiquitin/proteasome system plays the major role in the control of EPOR signaling. After EPO binding, EPOR is ubiquitinated and the intracellular part is degraded by the proteasome, preventing further signal transduction. The remaining part of the receptor and associated EPO are internalized and degraded by the lysosomes [<xref ref-type="bibr" rid="pfcp.REF.meyer.2007.5215">Meyer et al 2007</xref>]. The binding of p85, the regulatory subunit of phosphoinositide 3-kinase (PI3K), to phosphorylated residues Tyr429, Tyr431, or Tyr479, located in the C-terminal site of the cytoplasmic domain of EPOR, plays an important role in EPO-dependent EPOR internalization.</p>
          <p><bold>Abnormal gene product.</bold> Pathogenic variants in the cytoplasmic portion of EPOR identified in persons with PFCP result in truncated EPORs lacking the cytoplasmic COOH-terminal of the receptor, which contains a negative regulatory domain and is essential in SHP-1 phosphatase binding (a negative regulator of EPOR signaling). The lack of downregulation of EPOR after ligand binding results in increased proliferation rates due to the prolonged activation of JAK2-STAT5 and other signaling cascades and is responsible for the EPO hypersensitivity of erythroid progenitors observed in vitro in persons with PFCP [<xref ref-type="bibr" rid="pfcp.REF.huang.2010.844">Huang et al 2010</xref>].</p>
          <p>Using epidermal growth factor receptor-EPOR chimeras, <xref ref-type="bibr" rid="pfcp.REF.gross.2014.519">Gross et al [2014]</xref> recently described higher proliferation rates of UT7 cells associated with all <italic toggle="yes">EPOR</italic> pathogenic variants, including missense variants.</p>
        </sec>
      </sec>
      <sec id="pfcp.References">
        <title>References</title>
        <sec id="pfcp.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="pfcp.Literature_Cited.reflist0">
            <ref id="pfcp.REF.alsheikh.2008.1072">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Al-Sheikh</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazurier</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gardie</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casadevall</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galact&#x000e9;ros</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goossens</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wajcman</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pr&#x000e9;hu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ugo</surname>
                    <given-names>V.</given-names>
                  </name>
                </person-group>
                <article-title>A study of 36 unrelated cases with pure erythrocytosis revealed three new mutations in the erythropoietin receptor gene.</article-title>
                <source>Haematologica.</source>
                <year>2008</year>
                <volume>93</volume>
                <fpage>1072</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">18492694</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.arcasoy.1997.4628">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arcasoy</surname>
                    <given-names>MO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Degar</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forget</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <article-title>Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene.</article-title>
                <source>Blood.</source>
                <year>1997</year>
                <volume>89</volume>
                <fpage>4628</fpage>
                <lpage>35</lpage>
                <pub-id pub-id-type="pmid">9192789</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.bento.2013.361">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bento</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almeida</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maia</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Relvas</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oliveira</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girodon</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandez-Lago</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aguado-Diaz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraga</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Costa</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ara&#x000fa;jo</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silva</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vit&#x000f3;ria</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miguel</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silveira</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin-Nu&#x000f1;ez</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <source>Eur J Haematol.</source>
                <year>2013</year>
                <volume>91</volume>
                <fpage>361</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23859443</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.bento.2014.15">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bento</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Percy</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gardie</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maia</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Wijk</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perrotta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Della Ragione</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almeida</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girodon</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astr&#x000f6;m</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schnittger</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landin</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minkov</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Randi</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casadevall</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vainchenker</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rives</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermouet</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McMullin</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cario</surname>
                    <given-names>H</given-names>
                  </name>
                  <collab>ECE-Consortium</collab>
                </person-group>
                <article-title>Chauveau A, Gimenez-Roqueplo AP, Bressac-de-Paillerets B, Altindirek D, Lorenzo F, Lambert F, Dan H, Gad-Lapiteau S, Catarina Oliveira A, Rossi C, Fraga C, Taradin G, Martin-Nu&#x000f1;ez G, Vit&#x000f3;ria H, Diaz Aguado H, Palmblad J, Vid&#x000e1;n J, Relvas L, Ribeiro ML, Luigi Larocca M, Luigia Randi M, Pedro Silveira M, Percy M, Gross M, Marques da Costa R, Beshara S, Ben-Ami T, Ugo V; ECE-Consortium. Genetic basis of congenital erythrocytosis: mutation update and online databases.</article-title>
                <source>Hum Mutat.</source>
                <year>2014</year>
                <volume>35</volume>
                <fpage>15</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">24115288</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.bourantas.2006.537">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bourantas</surname>
                    <given-names>LK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chatzikyriakidou</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dasoula</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Syrrou</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bournatas</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Georgiou</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <article-title>Absence of mutations of the EPO-receptor gene in Greek patients with familial polycythemia.</article-title>
                <source>Eur J Haematol.</source>
                <year>2006</year>
                <volume>76</volume>
                <fpage>537</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16608505</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.cario.2013.1734">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cario</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McMullin</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bento</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pospisilova</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Percy</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hussein</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Astr&#x000f6;m</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hermouet</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>MPN&#x00026;MPNr-EuroNet. Erythrocytosis in children and adolescents - classification, characterization, and consensus recommendations for the diagnostic approach.</article-title>
                <source>Pediatr Blood Cancer.</source>
                <year>2013</year>
                <volume>60</volume>
                <fpage>1734</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23776154</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.chauveau.2016.475">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chauveau</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luque Paz</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lecucq</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Gac</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Le Mar&#x000e9;chal</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gueguen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berthou</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ugo</surname>
                    <given-names>V.</given-names>
                  </name>
                </person-group>
                <article-title>A new point mutation in EPOR inducing a short deletion in congenital erythrocytosis.</article-title>
                <source>Br J Haematol.</source>
                <year>2016</year>
                <volume>172</volume>
                <fpage>475</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">26010769</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.damen.1996.1455">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Damen</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krystal</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Early events in erythropoietin-induced signaling.</article-title>
                <source>Exp Hematol.</source>
                <year>1996</year>
                <volume>24</volume>
                <fpage>1455</fpage>
                <pub-id pub-id-type="pmid">8950227</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.damen.1995.5557">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Damen</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wakao</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krosl</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humphries</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutler</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krystal</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Tyrosine 343 in the erythropoietin receptor positively regulates erythropoietin-induced cell proliferation and STAT5 activation.</article-title>
                <source>EMBO J.</source>
                <year>1995</year>
                <volume>14</volume>
                <fpage>5557</fpage>
                <pub-id pub-id-type="pmid">8521813</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.de_la_chapelle.1993.4495">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de la Chapelle</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Traskelin</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Juvonen</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis.</article-title>
                <source>Proc Natl Acad Sci U S A.</source>
                <year>1993</year>
                <volume>90</volume>
                <fpage>4495</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">8506290</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.furukawa.1997.222">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Furukawa</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Narita</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakaue</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otsuka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuroha</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Masuko</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azegami</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kishi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Utsumi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koike</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aizawa</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Primary familial polycythaemia associated with a novel point mutation in the erythropoietin receptor.</article-title>
                <source>Br J Haematol.</source>
                <year>1997</year>
                <volume>99</volume>
                <fpage>222</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9359528</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.gobert.1996.2434">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gobert</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chretien</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gouilleux</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muller</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pallard</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Dusanter- Fourt I, Groner B, Lacombe C, Gisselbrecht S, Mayeux P. Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation.</article-title>
                <source>EMBO J.</source>
                <year>1996</year>
                <volume>15</volume>
                <fpage>2434</fpage>
                <pub-id pub-id-type="pmid">8665851</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.gross.2014.519">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gross</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben-Califa</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McMullin</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Percy</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bento</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cario</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minkov</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neumann</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Polycythaemia-inducing mutations in the erythropoietin receptor (EPOR): mechanism and function as elucidated by epidermal growth factor receptor - EPOR chimeras.</article-title>
                <source>Br J Haematol.</source>
                <year>2014</year>
                <volume>165</volume>
                <fpage>519</fpage>
                <lpage>28</lpage>
                <pub-id pub-id-type="pmid">24533580</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.huang.2010.844">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shen</surname>
                    <given-names>YM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bulut</surname>
                    <given-names>GB</given-names>
                  </name>
                </person-group>
                <article-title>Advances in understanding the pathogenesis of primary familial and congenital polycythaemia.</article-title>
                <source>Br J Haematol.</source>
                <year>2010</year>
                <volume>148</volume>
                <fpage>844</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">20096014</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.hussein.2012">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hussein</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Percy</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McMullin</surname>
                    <given-names>MF</given-names>
                  </name>
                </person-group>
                <article-title>Clinical utility gene card for: familial erythrocytosis.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2012</year>
                <volume>20</volume>
                <issue>5</issue>
                <pub-id pub-id-type="pmid">22274579</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.james.2005.546">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ugo</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casadevall</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Constantinescu</surname>
                    <given-names>SN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vainchenker</surname>
                    <given-names>W. A</given-names>
                  </name>
                </person-group>
                <article-title>JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.</article-title>
                <source>Trends Mol Med.</source>
                <year>2005</year>
                <volume>11</volume>
                <fpage>546</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">16271512</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.jedlickova.2003.327">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jedlickova</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockton</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prchal</surname>
                    <given-names>JT</given-names>
                  </name>
                </person-group>
                <article-title>Possible primary familial and congenital polycythemia locus at 7q22.1-7q22.2.</article-title>
                <source>Blood Cells Mol Dis.</source>
                <year>2003</year>
                <volume>31</volume>
                <fpage>327</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">14636647</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.kralovics.1997.2057">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kralovics</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Indrak</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stopka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berman</surname>
                    <given-names>BW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prchal</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prchal</surname>
                    <given-names>JT</given-names>
                  </name>
                </person-group>
                <article-title>Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias.</article-title>
                <source>Blood.</source>
                <year>1997</year>
                <volume>90</volume>
                <fpage>2057</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">9292543</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.kralovics.2001.115">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kralovics</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prchal</surname>
                    <given-names>JT</given-names>
                  </name>
                </person-group>
                <article-title>Genetic heterogeneity of primary familial and congenital polycythemia.</article-title>
                <source>Am J Hematol.</source>
                <year>2001</year>
                <volume>68</volume>
                <fpage>115</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">11559951</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.kralovics.1998.124">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kralovics</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sokol</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prchal</surname>
                    <given-names>JT</given-names>
                  </name>
                </person-group>
                <article-title>Absence of polycythemia in a child with a unique erythropoietin receptor mutation in a family with autosomal dominant primary polycythemia.</article-title>
                <source>J Clin Invest.</source>
                <year>1998</year>
                <volume>102</volume>
                <fpage>124</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9649565</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.lacombe.1999.22">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayeux</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>The molecular biology of erythropoietin.</article-title>
                <source>Nephrol Dial Transplant.</source>
                <year>1999</year>
                <volume>14</volume>
                <supplement>Suppl 2</supplement>
                <fpage>22</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10334664</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.lodish.1992.95">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lodish</surname>
                    <given-names>HF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilton</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longmore</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watowich</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshimura</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>The erythropoietin receptor: dimerization, activation, and tumorigenesis.</article-title>
                <source>Cold Spring Harb Symp Quant Biol.</source>
                <year>1992</year>
                <volume>57</volume>
                <fpage>95</fpage>
                <lpage>106</lpage>
                <pub-id pub-id-type="pmid">1339709</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.mcmullin.2005.174">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McMullin</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bareford</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harrison</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hunt</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oscier</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polkey</surname>
                    <given-names>MI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reilly</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenthal</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryan</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pearson</surname>
                    <given-names>TC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilkins</surname>
                    <given-names>B</given-names>
                  </name>
                  <collab>General Haematology Task Force of the British Committee for Standards in Haematology</collab>
                </person-group>
                <article-title>Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis.</article-title>
                <source>Br J Haematol.</source>
                <year>2005</year>
                <volume>130</volume>
                <fpage>174</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">16029446</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.mcmullin.2015.586">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McMullin</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bento</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rainey</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girodon</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cario</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Outcomes of pregnancy in patients with congenital erythrocytosis.</article-title>
                <source>Br J Haematol.</source>
                <year>2015</year>
                <volume>170</volume>
                <fpage>586</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">25732921</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.mcmullin.2016.248">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McMullin</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cario</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>LNK mutations and myeloproliferative disorders.</article-title>
                <source>Am J Hematol.</source>
                <year>2016</year>
                <volume>91</volume>
                <fpage>248</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">26660394</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.meyer.2007.5215">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deau</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forejtnikova</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dumenil</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Margottin-Goguet</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayeux</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verdier</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Beta-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation.</article-title>
                <source>Blood.</source>
                <year>2007</year>
                <volume>109</volume>
                <fpage>5215</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">17327410</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.miura.1994.1501">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miura</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quelle</surname>
                    <given-names>FW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Witthuhn</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ilhe</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aoki</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor.</article-title>
                <source>Blood.</source>
                <year>1994</year>
                <volume>84</volume>
                <fpage>1501</fpage>
                <pub-id pub-id-type="pmid">8068943</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.nakamura.1992.1138">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Komatsu</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakauchi</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells.</article-title>
                <source>Science.</source>
                <year>1992</year>
                <volume>257</volume>
                <fpage>1138</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">1324524</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.nosaka.1999.4754">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nosaka</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawashima</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Misawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikuta</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mui</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitamura</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Stat5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells.</article-title>
                <source>EMBO J.</source>
                <year>1999</year>
                <volume>18</volume>
                <fpage>4754</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">10469654</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.percy.1998.407">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Percy</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McMullin</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roques</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westwood</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acharya</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lappin</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pearson</surname>
                    <given-names>TC</given-names>
                  </name>
                </person-group>
                <article-title>Erythrocytosis due to a mutation in the erythropoietin receptor gene.</article-title>
                <source>Br J Haematol.</source>
                <year>1998</year>
                <volume>100</volume>
                <fpage>407</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">9488636</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.petersen.2004.537">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Petersen</surname>
                    <given-names>KB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hokland</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petersen</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nyvold</surname>
                    <given-names>CG</given-names>
                  </name>
                </person-group>
                <article-title>Erythropoietin receptor defect: a cause of primary polycythemia.</article-title>
                <source>Br J Haematol.</source>
                <year>2004</year>
                <volume>125</volume>
                <fpage>537</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15142125</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.prchal.1985.1208">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Prchal</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crist</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldwasser</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perrine</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prchal</surname>
                    <given-names>JF</given-names>
                  </name>
                </person-group>
                <article-title>Autosomal dominant polycythemia.</article-title>
                <source>Blood.</source>
                <year>1985</year>
                <volume>66</volume>
                <fpage>1208</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">4052634</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.prchal.1995.1831">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Prchal</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Semenza</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prchal</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sokol</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>Familial polycythemia.</article-title>
                <source>Science.</source>
                <year>1995</year>
                <volume>268</volume>
                <fpage>1831</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">7604250</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.prchal.1996.263">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Prchal</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sokol</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>"Benign erythrocytosis" and other familial and congenital polycythemias.</article-title>
                <source>Eur J Haematol.</source>
                <year>1996</year>
                <volume>57</volume>
                <fpage>263</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">8982288</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.rives.2007.674">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rives</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pahl</surname>
                    <given-names>HL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Florensa</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellosillo</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neusuess</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estella</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Debatin</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohne</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cario</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis.</article-title>
                <source>Haematologica.</source>
                <year>2007</year>
                <volume>92</volume>
                <fpage>674</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17488692</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.socolovsky.1999.181">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Socolovsky</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fallon</surname>
                    <given-names>AEJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brugnara</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lodish</surname>
                    <given-names>HF</given-names>
                  </name>
                </person-group>
                <article-title>Fetal anemia and apoptosis of red cell progenitors in Stat5a/5b mice, a direct role for Stat5 in Bcl-XL induction.</article-title>
                <source>Cell.</source>
                <year>1999</year>
                <volume>98</volume>
                <fpage>181</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">10428030</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.sokol.1995.15">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sokol</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luhovy</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guan</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prchal</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Semenza</surname>
                    <given-names>GL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prchal</surname>
                    <given-names>JT</given-names>
                  </name>
                </person-group>
                <article-title>Primary familial polycythemia: a frameshift mutation in the erythropoietin receptor gene and increased sensitivity of erythroid progenitors to erythropoietin.</article-title>
                <source>Blood.</source>
                <year>1995</year>
                <volume>86</volume>
                <fpage>15</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">7795221</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.sokol.1994.447">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sokol</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prchal</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x02019;Andrea</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rado</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prchal</surname>
                    <given-names>JT</given-names>
                  </name>
                </person-group>
                <article-title>Mutation in the negative regulatory element of the erythropoietin receptor gene in a case of sporadic primary polycythemia.</article-title>
                <source>Exp Hematol.</source>
                <year>1994</year>
                <volume>22</volume>
                <fpage>447</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">8174675</pub-id>
              </element-citation>
            </ref>
            <ref id="pfcp.REF.witthuhn.1993.227">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Witthuhn</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quelle</surname>
                    <given-names>FW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silvennoinen</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miura</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ihle</surname>
                    <given-names>JN</given-names>
                  </name>
                </person-group>
                <article-title>JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.</article-title>
                <source>Cell.</source>
                <year>1993</year>
                <volume>74</volume>
                <fpage>227</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">8343951</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="pfcp.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="pfcp.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>10 November 2016 (bp) Review posted live</p>
            </list-item>
            <list-item>
              <p>21 October 2015 (ch) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
